KR101726555B1 - ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체 - Google Patents

ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체 Download PDF

Info

Publication number
KR101726555B1
KR101726555B1 KR1020177003335A KR20177003335A KR101726555B1 KR 101726555 B1 KR101726555 B1 KR 101726555B1 KR 1020177003335 A KR1020177003335 A KR 1020177003335A KR 20177003335 A KR20177003335 A KR 20177003335A KR 101726555 B1 KR101726555 B1 KR 101726555B1
Authority
KR
South Korea
Prior art keywords
phenyl
substituted
dihydro
alkyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177003335A
Other languages
English (en)
Korean (ko)
Other versions
KR20170017015A (ko
Inventor
샤오징 후
페이 왕
지구오 수
얀핑 왕
인시앙 왕
Original Assignee
베타 파머수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베타 파머수티컬 컴퍼니 리미티드 filed Critical 베타 파머수티컬 컴퍼니 리미티드
Publication of KR20170017015A publication Critical patent/KR20170017015A/ko
Application granted granted Critical
Publication of KR101726555B1 publication Critical patent/KR101726555B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020177003335A 2012-06-29 2013-07-01 ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체 Expired - Fee Related KR101726555B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/077924 2012-06-29
CN2012077924 2012-06-29
PCT/CN2013/078592 WO2014000713A1 (en) 2012-06-29 2013-07-01 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157002238A Division KR101726522B1 (ko) 2012-06-29 2013-07-01 ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체

Publications (2)

Publication Number Publication Date
KR20170017015A KR20170017015A (ko) 2017-02-14
KR101726555B1 true KR101726555B1 (ko) 2017-04-12

Family

ID=49782283

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157002238A Expired - Fee Related KR101726522B1 (ko) 2012-06-29 2013-07-01 ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체
KR1020177003331A Expired - Fee Related KR101770545B1 (ko) 2012-06-29 2013-07-01 ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체
KR1020177003335A Expired - Fee Related KR101726555B1 (ko) 2012-06-29 2013-07-01 ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020157002238A Expired - Fee Related KR101726522B1 (ko) 2012-06-29 2013-07-01 ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체
KR1020177003331A Expired - Fee Related KR101770545B1 (ko) 2012-06-29 2013-07-01 ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체

Country Status (14)

Country Link
US (1) US9617257B2 (enExample)
EP (1) EP2867223B1 (enExample)
JP (1) JP6059342B2 (enExample)
KR (3) KR101726522B1 (enExample)
AU (1) AU2013283993B2 (enExample)
BR (1) BR112014032745B1 (enExample)
CA (1) CA2878049C (enExample)
ES (1) ES2698511T3 (enExample)
IN (1) IN2015DN00372A (enExample)
RU (1) RU2619130C2 (enExample)
SG (1) SG11201408750VA (enExample)
TW (1) TWI520962B (enExample)
WO (1) WO2014000713A1 (enExample)
ZA (1) ZA201500344B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
AU2016297395B2 (en) * 2015-07-20 2019-01-17 Betta Pharmaceuticals Co., Ltd Crystalline form of fused pyridine derivative's maleate and uses thereof
CN106924260B (zh) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
HUE058802T2 (hu) 2016-12-09 2022-09-28 Denali Therapeutics Inc RIPK1 inhibitorokként alkalmas vegyületek
AU2018272986A1 (en) * 2017-05-26 2019-12-12 Ichnos Sciences SA Novel inhibitors of MAP4K1
WO2018233527A1 (zh) * 2017-06-19 2018-12-27 上海和誉生物医药科技有限公司 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用
CN109988108B (zh) * 2017-12-29 2022-04-29 江苏豪森药业集团有限公司 一种卡博替尼的制备方法
SG11202105872RA (en) * 2018-12-14 2021-07-29 Beta Pharma Inc Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TWI812301B (zh) * 2021-06-24 2023-08-11 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物
US11999750B2 (en) 2022-01-12 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
EP4289427A1 (en) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058891A1 (de) 2003-12-09 2005-06-30 Bayer Healthcare Ag Pyrrolopyridin-substituierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
WO2006116713A1 (en) 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4750701B2 (ja) * 2003-07-07 2011-08-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング マロンアミド誘導体
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5368701B2 (ja) * 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
ES2438017T3 (es) * 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
JP2008521900A (ja) * 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
DK1904504T3 (da) * 2005-05-20 2014-06-23 Methylgene Inc Inhibitorer af vegf-receptor- og hgf-receptorsignalering
WO2008049855A2 (en) * 2006-10-27 2008-05-02 Glaxo Group Limited 7-azaindole derivatives as c-met kinase inhibitors
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
KR100961410B1 (ko) * 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
CN102086211B (zh) * 2009-12-08 2013-09-11 广东东阳光药业有限公司 作为蛋白激酶抑制剂的芳杂环化合物
CA2805148C (en) * 2010-07-14 2016-01-19 Zhejiang Beta Pharma Inc. Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058891A1 (de) 2003-12-09 2005-06-30 Bayer Healthcare Ag Pyrrolopyridin-substituierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
WO2006116713A1 (en) 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
RU2015102057A (ru) 2016-08-20
SG11201408750VA (en) 2015-01-29
WO2014000713A1 (en) 2014-01-03
RU2619130C2 (ru) 2017-05-12
KR101726522B1 (ko) 2017-04-12
EP2867223B1 (en) 2018-09-05
JP2015521634A (ja) 2015-07-30
ES2698511T3 (es) 2019-02-05
US9617257B2 (en) 2017-04-11
BR112014032745A2 (pt) 2017-06-27
AU2013283993B2 (en) 2016-07-07
US20150315210A1 (en) 2015-11-05
TW201418254A (zh) 2014-05-16
BR112014032745B1 (pt) 2022-01-04
CA2878049A1 (en) 2014-01-03
KR20150031320A (ko) 2015-03-23
ZA201500344B (en) 2016-08-31
EP2867223A4 (en) 2016-01-06
TWI520962B (zh) 2016-02-11
HK1207642A1 (en) 2016-02-05
EP2867223A1 (en) 2015-05-06
JP6059342B2 (ja) 2017-01-11
IN2015DN00372A (enExample) 2015-06-12
KR101770545B1 (ko) 2017-08-22
AU2013283993A1 (en) 2015-02-05
KR20170017014A (ko) 2017-02-14
CA2878049C (en) 2016-12-13
KR20170017015A (ko) 2017-02-14

Similar Documents

Publication Publication Date Title
KR101726555B1 (ko) ｃ―ＭＥＴ 타이로신 키나제 억제제로서 유용한 신규한 축합 피리딘 유도체
KR101538707B1 (ko) c-MET 티로신 키나제 억제제로서 유용한 신규 융합된 헤테로사이클릭 유도체
TWI713952B (zh) 作為溴結構域蛋白質抑制劑的化合物和組合物
KR20160111395A (ko) 단백질 키나제의 조절인자로서의 다이아릴 거대환
KR102826937B1 (ko) Axl 및 c-Met 키나아제 억제 활성을 갖는 화합물 및 이의 제조와 응용
KR20160005354A (ko) [1,2,4]트라이아졸[4,3-에이]피리딘 유도체, 그의 제조 방법 또는 그의 의학적 용도
CN115141202A (zh) 嘧啶并吡嗪酮化合物及其用途
CN115836064B (zh) 具有egfr抑制活性的三嗪衍生物及其制备方法和应用
JP6594862B2 (ja) 五員複素環縮合ピリジン系化合物、並びにその調製方法および用途
TW202017928A (zh) 新穎三環化合物
CN104507930B (zh) 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物
CA3153600C (en) Compound having axl and c-met kinase inhibitory activity, preparation thereof and application thereof
HK1207642B (en) Novel fused pyridine derivatives useful as c-met tyrosine kinase inhibitors
CN119013283A (zh) 大环egfr抑制剂及其制备方法和药学上的应用
TW202448895A (zh) 作為egfr抑制劑之大環胺基吡啶化合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20220407

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220407

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000